Q-omics provides the consensus-scored STEAP4 profile across patient tissues and cancer cell-line models. STEAP4 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, STEAP4 is differentially expressed in 15, with the highest sampling consensus in LUSC. Additionally, STEAP4 protein abundance shows 35,217 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LIHC, LUSC, and LSCC as cancer lineages where STEAP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STEAP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STEAP4 survival associations across molecular data types. STEAP4 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STEAP4 RNA expression–survival associations across cancer types. High STEAP4 expression shows unfavorable associations in STAD, KIRP and OV, but favorable associations in LIHC, ESCA and ACC. The LIHC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for STEAP4 RNA expression.
This table summarizes STEAP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 11. The strongest signals are observed in LUSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for STEAP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STEAP4 shows lower tumor expression in LUSC, LIHC, COAD, KICH and BLCA and higher tumor expression in KIRC. The LUSC box plot shows higher STEAP4 RNA expression in normal versus tumor tissue (log2 FC = −4.295, t-test p < 0.001).
This table shows molecular features associated with STEAP4 in patient tissues and cancer cell lines. In patient samples, STEAP4 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, STEAP4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LUNG_NSCLC_LUAD.
